CSL Limited · ASX:CSL
CSL — Shareholder Meeting (October 2009)
17 slides from CSL's shareholder meeting presentation, October 2009
Slide 1: CSL Limited Annual General Meeting
CSL LIMITED ANNUAL GENERAL MEETING CSL
Slide 2: Disclaimer
Disclaimer Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about our financial results and estimates, business prospects and products in research that involve substantial risks and uncertainties, many
Slide 3: Highlights - Financial
Highlights - Financial Total revenue $5.04 billion up 32% (16% at constant currency*) • HPV royalties of $161m EBIT $1.37 billion up 42% (21% at constant currency) NPAT $1.15 billion up 63% Underlying operational profit $1.02 billion up 45% - adjusted for • Talecris merger discontinuation, favourabl
Slide 4: Underlying Operational Profit up 45%
Underlying Operational Profit up 45% (23% @ CC) $1,146m Merger Disc* Notes Tax Reported NPAT $1,146m +45% $1,020m Underlying NPAT - non operational items: Operational Profit - Merger discontinuation* $ 79m $702m - Tax non operational $ 47m $126m Underlying operational profit** $1,020m Jun 08 Jun 09
Slide 5: Global Revenue $5 Billion
Global Revenue $5 Billion* Rest of World Australia 8% North America 15% 38% Asia 9% Europe 30% * Chart excludes revenues related to the discontinuation of the Talecris merger 5
Slide 6: Human Health Business Unit Performance
Human Health Business Unit Performance • CSL Behring • Other Human Health - CSL Bioplasma - CSL Biotherapies - CSL Research & Development
Slide 7: CSL Behring
CSL Behring • Sales US$2,781m (A$3,786m) • Product sales up 17% at constant currency* (cc) • EBITDA margin ~34%, up ~3% at cc • Strong contribution from core and specialty products • Optimizing product mix • Privigen® conversion • Vivaglobin® take-up • Privigen® IG Lab Module 1 plant approved • RiaS
Slide 8: CSL Behring – Product sales up 17% in CC terms
CSL Behring – Product sales up 17% in CC terms US$2,781m US$2,525m Other 2,500 Immuno- globulins 2,000 1,500 Wound H Critical Care 1,000 pdCoag 500 Helixate 0 Jun 08 Sales for the 12 month period Jun 09 8
Slide 9: CSL Bioplasma
CSL Bioplasma Sales A$334m up 32% (23% at constant currency) Strong Albumin demand and improved pricing in China Australian sales up 8% Biostate® approved for von Willebrands disease in Australia Clinical trials on Intragam® 10 NF completed • Dossier submitted to TGA Phase III trial - subcutaneous I
Slide 10: CSL Biotherapies
CSL Biotherapies Sales A$502m up 5% GARDASIL® Australia / New Zealand GARDASIL® sales in Australia $159m • >75% of females aged 12 to 26 now vaccinated New Zealand sales of $26m Influenza sales $124m, up 60% Dispensing and packaging facilities completed at Kankakee site • US FDA approved August 2009
Slide 11: Pandemic Influenza Vaccine H1N1
Pandemic Influenza Vaccine H1N1 Significant orders US Department of Health and Human Services • Initial order US$180m vaccine Australian Department of Health and Ageing • Order for 21 million doses (15 mcg) Initial industry yields lower than anticipated Extensive clinical program underway Excellent
Slide 12: R&D Investment
R&D Investment Growth in new product and market development $Am FY2010 ~$340m $312 300 250 $225 New Product Development 200 $191 150 Market Development 100 50 Life Cycle Management 0 FY2007 FY2008 FY2009 12
Slide 13: R&D Highlights
R&D Highlights IgPro20 • Phase 3 completed and BLA submitted to FDA April 2009 RiaSTAP™ • FDA approval Jan 2009 and EU submission Feb 2009 Berinert® • US FDA approved Oct 2009 Recombinant Factor IX-FP • Lead clone selected and manufacturing cell line established Reconstituted HDL • Reformulation com
Slide 14: Group Outlook for FY2010
Group Outlook for FY2010 Foreign Exchange (post tax) FY10 Est. Translation* -ve $100m Transaction -ve $80m – $90m Total -ve $180m – $200m Net profit after tax NPAT FY2010 at constant currency $1,160m - $1,260m Up 14-24% on FY09 underlying operational profit Est. foreign currency NPAT impact -ve $180
Slide 15: CSL Growth Strategy
CSL Growth Strategy Market Royalties & Novel Development Licensing Products HPV Biotech Influenza H1N1 rCoag Privigen® Pro20 ISCOMATRIX® CSL 360 Specialty products adjuvant Plasma RiaSTAP™ Zemaira® Technology rHDL Cytogam® vWF partnering Beriplex® etc Expanded geographies Global Specialty Bio- pharm
Slide 16: Appendix
CSL Limited Annual General Meeting Appendix
Slide 17: Foreign Exchange Sensitivity
Foreign Exchange Sensitivity Translation sensitivity to 1% movement in key currency pairs Translation impact - 9 months to June ‘10 NPAT 9 Oct 1% rate change Rates 9 months to June ‘10 • AUD/USD* 0.90 +/- $1.0m • AUD/EUR 0.61 +/- $2.9m • AUD/CHF 0.92 +/- $3.0m $6.9m * Includes GARDASIL Royalties 17